The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer
| Autor: | Hans Morreau, Els J. M. Nieveen van Dijkum, Inne H.M. Borel Rinkes, Susanne van Eeden, Abbey Schepers, Bettien M. van Hemel, Ilse van Engen-van Grunsven, Paul J. van Diest, Menno R. Vriens, Thera P. Links, Han J. Bonenkamp, Gerlof D. Valk, Koen M.A. Dreijerink, Lutske Lodewijk, Bart de Keizer, Schelto Kruijff, Stefan M. Willems |
|---|---|
| Přispěvatelé: | Internal medicine, CCA - Cancer biology and immunology, Pathology, Amsterdam Gastroenterology Endocrinology Metabolism, AII - Inflammatory diseases, Surgery, AGEM - Digestive immunity, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON) |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Glutamate Carboxypeptidase II
Male 0301 basic medicine Time Factors Databases Factual NEOVASCULATURE Prostate-specific membrane antigen urologic and male genital diseases THERAPY Theranostic Nanomedicine Tissue microarray Imaging Prostate cancer Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] 0302 clinical medicine Risk Factors Lymph node Netherlands Medullary thyroid cancer Thyroid Middle Aged Primary tumor Immunohistochemistry Progression-Free Survival Molecular Imaging medicine.anatomical_structure Lymphatic Metastasis 030220 oncology & carcinogenesis Antigens Surface Female Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] Adult CARCINOMA Risk Assessment Pathology and Forensic Medicine 03 medical and health sciences All institutes and research themes of the Radboud University Medical Center Biomarkers Tumor medicine PSMA Humans Thyroid Neoplasms business.industry medicine.disease Theranostics Carcinoma Neuroendocrine 030104 developmental biology Monoclonal Antibody J591 PET Tissue Array Analysis Positron-Emission Tomography Microvessels Cancer research MONOCLONAL-ANTIBODY J591 business |
| Zdroj: | Human Pathology, 81, 245-254 Human Pathology, 81, 245-254. W.B. Saunders Ltd Human pathology, 81, 245-254. W.B. Saunders Ltd Human Pathology, 81, pp. 245-254 Human Pathology, 81, 245-254. W B SAUNDERS CO-ELSEVIER INC Lodewijk, L, Willems, S M, Dreijerink, K M A, de Keizer, B, van Diest, P J, Schepers, A, Morreau, H, Bonenkamp, H J, Van Engen-van Grunsven, I A C H, Kruijff, S, van Hemel, B M, Links, T P, van Dijkum, E N, van Eeden, S, Valk, G D, Borel Rinkes, I H M & Vriens, M R 2018, ' The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid Cancer ', Human Pathology, vol. 81, pp. 245-254 . https://doi.org/10.1016/j.humpath.2018.06.035 Human Pathology, 81, 245. W.B. Saunders Ltd |
| ISSN: | 0046-8177 |
| DOI: | 10.1016/j.humpath.2018.06.035 |
| Popis: | Summary Medullary thyroid cancer (MTC) accounts for 4% of all thyroid cancers and originates from the parafollicular C-cells. Prostate-specific membrane antigen (PSMA) is known for its expression in the epithelium of prostate cancer and has been demonstrated to be useful both for therapeutic and diagnostic purposes as a so-called theranostic target. As PSMA is also expressed in the neovasculature of other solid tumor types, our aim was to assess PSMA expression and its prognostic role in MTC. Tissues from patients that underwent surgery for MTC between 1988 and 2014 in five tertiary referral centers in The Netherlands were included in a tissue microarray. Using immunohistochemistry, total numbers of PSMA and CD31-positive microvessels were evaluated. Results showed that 92% of MTC expressed PSMA in the neovasculature, whereas the tumor cells were consistently negative. The average number of PSMA-positive microvessels did not differ significantly between the primary tumor and initial lymph node metastases (P = .09), nor between initial and recurrent lymph node metastases (P = 1.00). The PSMA score was found to be correlated with progression-free survival and overall survival. In multivariate analysis, a higher number of PSMA-positive microvessels was associated with favorable prognosis (odds ratio 3.6; 95% confidence interval 1.0–12.8; P = .05). In conclusion, over 90% of MTC appears to express PSMA in the neovasculature. A higher number of PSMA-positive microvessels is prognostically favorable. Since it is highly expressed in MTC, PSMA is an interesting novel target for imaging and potentially also as a target for peptide radioligand therapy in MTC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect